Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer

dc.contributor.author	Ζησιμόπουλος, Αθανάσιος Σ.	el
dc.contributor.author	Στέλλος, Κώστας	el
dc.contributor.author	Ματθαίος, Δ.	el
dc.contributor.author	Πετράκης, Γ.	el
dc.contributor.author	Παρμενοπούλου, Β.	el
dc.date.accessioned	2015-04-24T09:18:51Z
dc.date.issued	2015-04-24
dc.identifier.uri	http://hdl.handle.net/11400/8835
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	http://www.scopus.com	en
dc.subject	καρκίνος του μαστού
dc.subject	καρκίνος του προστάτη
dc.subject	Breast cancer
dc.subject	Prostate cancer
dc.title	Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer	en
heal.type	journalArticle
heal.secondaryTitle	Comparison to cea, ca 15-3, psa and bone scintigraphy	en
heal.classification	Ιατρική
heal.classification	Καρκίνος
heal.classification	Medicine
heal.classification	Cancer
heal.classificationURI	N/A-Ιατρική
heal.classificationURI	N/A-Καρκίνος
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh00006614
heal.classificationURI	http://skos.um.es/unescothes/C00499
heal.contributorName	Μπαμπάτσικου, Φωτούλα Π.	el
heal.contributorName	Ματθαίου, Ε.	el
heal.contributorName	Θεοδοσιάδου, Αικατερίνη Κ.	el
heal.contributorName	Κουτής, Χαρίλαος	el
heal.identifier.secondary	ISSN: 11070625
heal.dateAvailable	10000-01-01
heal.language	en
heal.access	forever
heal.publicationDate	2009
heal.abstract	Purpose: In this study we evaluated the clinical usefulness of serum pro-I collagen peptide (PICP) and I collagen telopeptide (ICTP) as indicators of early bone metastases in patients with breast (BC), lung (LC), urinary bladder (UBC) and prostate cancer (PC). Patients and methods: 305 patients were examined. 145 had histologically confirmed BC (92 with bone metastases), 20 UBC (6 with bone metastases), 11 LC (3 with bone metastases) and 129 PC (68 with bone metastases). In BC patients we compared the PICP and ICTP levels with those of CA 15-3, CEA and bone scintigraphy. Patients with LC and UBC had PICP and ICTP measurements, PC patients had serum PICP, prostate specific antigen (PSA) measurements and bone scans. 104 healthy individuals served as controls. Results: ICTP and CA 15-3 levels were significantly higher in patients with BC and bone metastases in comparison to patients without metastases (p <0.05), while PICP and CEA were only marginally higher. Significant correlation was observed between existence of bone metastases and ICTP levels (p <0.05). The sensitivity of PICP, ICTP, CEA and CA 15-3 was 28.1, 48.6, 42, and 78%, respectively and specificity was 83.9, 94, 65 and 86%, respectively. ICTP and CA 15-3 were the most reliable markers for early diagnosis of bone metastases in BC. PICP alone or with ICTP were not sensitive enough. Only CA 15-3 showed sensitivity 78% and specificity 86%. When combined CA 15-3, ICTP and CEA the sensitivity and specificity increased to 82% and 96%, respectively. Furthermore, PICP and PSA levels were significantly higher in patients with PC and bone metastases in comparison to patients with benign prostate hyperplasia (BPH) (p <0.0001) or in patients with PC without bone metastases (p <0.0005 for PICP and p <0.0001 for PSA). The co-evaluation of PICP and PSA improved the sensitivity (78%), specificity (96%), accuracy (97%) and positive predictive value (97%). In LC patients, ICTP levels differed significantly between patients with and without bone metastases (p=0.025). In UBC patients, PICP levels differed significantly between patients with and without bone metastases (p=0.017). Conclusion: ICTP and CA 15-3 are the most reliable markers for early diagnosis of bone metastases in BC patients. PICP could be useful for diagnosing early bone metastases of PC and combined with PSA and bone scan can be an additional tool in the follow-up of PC patients. For LC patients, ICTP showed a significant difference in the discrimination of patients with and without bone metastases. In UBC patients, PICP showed a significant difference in the discrimination of patients with and without bone metastases.	el
heal.journalName	Journal of B.U.ON.	en
heal.journalType	peer-reviewed
heal.fullTextAvailability	false